Loading
A phase 2 trial of Carboplatin, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by iTeos Therapeutics, active and no longer recruiting.
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05403385 by iTeos Therapeutics, with 36 participants enrolled, started 2022-08-26 and due to reach its primary completion in 2025-06-13. Interventions recorded: inupadenant, Placebo, Carboplatin, Pemetrexed. Conditions listed: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.